Superantigen-like effects of a Candida albicans polypeptide

Journal of Infectious Diseases

Volumn 197, Issue 7, 2008, Pages 981-989

  Devore Carter, Denise ^a   Kar, Sujata ^a   Vellucci, Vincent ^a   Bhattacherjee, Vasker ^a,c   Domanski, Paul ^b   Hostetter, Margaret K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Inhibitex   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; EPITOPE; FUNGAL PROTEIN; GAMMA INTERFERON; HISTIDINE; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MAM ANTIGEN; MONOCLONAL ANTIBODY; POLYPEPTIDE; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA; WNT1 PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOKINE RELEASE; FUNGEMIA; HUMAN; HUMAN CELL; MYCOPLASMA ARTHRITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION;

CANDIDA ALBICANS; CELL ADHESION MOLECULES; CYTOKINES; FUNGAL PROTEINS; GENE DELETION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOCYTE ACTIVATION; MYCOPLASMA ARTHRITIDIS; PROTEIN BINDING; SUPERANTIGENS; T-LYMPHOCYTE SUBSETS; URINE;

EID: 42549150721     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/529203     Document Type: Article

References (47)

1. Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998; 19:846-50.
2. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44:747-51.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239-44.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
5. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167:1247-51.
6. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41:1232-9.
7. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-43.
8. Braude AI, Rock JA. The syndrome of acute disseminated moniliasis in adults. AMA Arch Intern Med 1959; 104:91-100.
9. Presterl E, Lassnigg A, Mueller-Uri P, El-Menyawi I, Graninger W. Cytokines in sepsis due to Candida albicans and in bacterial sepsis. Eur Cytokine Netw 1999; 10:423-30.
10. Faix RG. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 1992; 11:88-93.
11. Kupfahl C, Ruppert T, Dietz A, Geginat G, Hof H. Candida species fail to produce the immunosuppressive secondary metabolite gliotoxin in vitro. FEMS Yeast Res 2007; 7:986-92.
12. Walsh P, Norris DA, Abe J, Martin DK, Giorno R, Leung DY. Candida albicans induces selective expansion of human T lymphocytes expressing the T-cell receptor variable region Vβ 5.1. J Dermatol Sci 1996; 12:140-6.
13. Gale C, Finkel D, Tao N, et al. Cloning and expression of a gene encoding an integrin-like protein in Candida albicans. Proc Natl Acad Sci U S A 1996; 93:357-61.
14. Gale CA, Bendel CM, McClellan M, et al. Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 1998; 279:1355-8.
15. Cole BC, Knudtson KL, Oliphant A, et al. The sequence of the Mycoplasma arthritidis superantigen, MAM: identification of functional domains and comparison with microbial superantigens and plant lectin mitogens. J Exp Med 1996; 183:1105-10.
16. Wilson RB, Davis D, Mitchell AP. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol 1999; 181:1868-74.
17. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134:717-28.
18. Liu H, Kohler J, Fink GR. Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 1994; 266:1723-6.
19. Davis D, Wilson RB, Mitchell AP. RIM101-dependent and -independent pathways govern pH responses in Candida albicans. Molec Cell Biol 2000; 20:971-8.
20. Hoffman CS, Winston F. A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene 1987; 57:267-72.
21. Ohama T, Suzuki T, Mori M, et al. Non-universal decoding of the leucine codon CUG in several Candida species. Nucleic Acids Res 1993; 21:4039-45.
22. Santos MA, Tuite MF. The CUG codon is decoded in vivo as serine and not leucine in Candida albicans. Nucleic Acids Res 1995; 23:1481-6.
23. Pfaller MA, Bale M, Buschelman B, et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol 1995; 33:1104-7.
24. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39:2520-2.
25. Moreno J, Lipsky PE. Differential ability of fixed antigen-presenting cells to stimulate nominal antigen-reactive and alloreactive T4 lymphocytes. J Immunol 1986; 136:3579-87.
26. Kappler J, Kotzin B, Herron L, et al. Vβ-specific stimulation of human T cells by staphylococcal toxins. Science 1989; 244:811-3.
27. Fleischer B, Gerardy-Schahn R, Metzroth B, Carrel S, Gerlach D, Kohler W. An evolutionary conserved mechanism of T cell activation by microbial toxins: evidence for different affinities of T cell receptor-toxin interaction. J Immunol 1991; 146:11-7.
28. Norrby-Teglund A, Chatellier S, Low DE, McGeer A, Green K, Kotb M. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 2000; 30:3247-55.
29. Cameron SB, Nawijn MC, Kum WW, Savelkoul HF, Chow AW. Regulation of helper T cell responses to staphylococcal superantigens. Eur Cytokine Netw 2001; 12:210-22.
30. Levitz SM, North EA. Gamma interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans. Infect Immun 1996; 64:1595-9.
31. Al-Daccak R, Mehindate K, Damdoumi F, et al. Staphylococcal enterotoxin D is a promiscuous superantigen offering multiple modes of interactions with the MHC class II receptors. J Immunol 1998; 160:225-32.
32. Hoffman M, Tremaine M, Mansfield J, Betley M. Biochemical and mutational analysis of the histidine residues of staphylococcal enterotoxin A. Infect Immun 1996; 64:885-90.
33. Kokan-Moore NP, Bergdoll MS. Effect of chemical modification of histidine and tyrosine residues in toxic shock syndrome toxin 1 on the serologic and mitogenic activities of the toxin. Infect Immun 1989; 57:1901-5.
34. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54:99-166.
35. Mu HH, Humphreys J, Chan FV, Cole BC. TLR2 and TLR4 differentially regulate B7-1 resulting in distinct cytokine responses to the mycoplasma superantigen MAM as well as to disease induced by Mycoplasma arthritidis. Cell Microbiol 2006; 8:414-26.
36. Earhart CA, Mitchell DT, Murray DL, et al. Structures of five mutants of toxic shock syndrome toxin-1 with reduced biological activity. Biochemistry 1998; 37:7194-202.
37. Gale C, Gerami-Nejad M, McClellan M, Vandoninck S, Longtine MS, Berman J. Candida albicans Int1p interacts with the septin ring in yeast and hyphal cells. Mol Biol Cell 2001; 12:3538-49.
38. Netea MG, Gow NA, Munro CA, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006; 116:1642-50.
39. Timpel C, Strahl-Bolsinger S, Ziegelbauer K, Ernst JF. Multiple functions of Pmt1p-mediated protein O-mannosylation in the fungal pathogen Candida albicans. J Biol Chem 1998; 273:20837-46.
40. Timpel C, Zink S, Strahl-Bolsinger S, Schroppel K, Ernst J. Morphogenesis, adhesive properties, and antifungal resistance depend on the Pmt6 protein mannosyltransferase in the fungal pathogen Candida albicans. J Bacteriol 2000; 182:3063-71.
41. Hogan RJ, VanBeek J, Broussard DR, Surman SL, Woodland DL. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells. J Immunol 2001; 166:6514-22.
42. Li H, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol 1999; 17:435-66.
43. Tada H, Nemoto E, Shimauchi H, et al. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol 2002; 46:503-12.
44. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2:e35.
45. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185:1483-9.
46. Riddell LA, Pinching AJ, Hill S, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17:789-97.
47. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8:1398-404.